MGTA - Magenta Therapeutics, Inc. Stock Price, Fair Value and News

Market Closed

MGTA Stock Price

View Fullscreen

MGTA RSI Chart

MGTA Valuation

Market Cap

21.8M

Price/Earnings (Trailing)

-0.44

Price/Sales (Trailing)

2.59

Price/Free Cashflow

-1.32

MGTA Price/Sales (Trailing)

MGTA Profitability

Return on Equity

-13.46%

Return on Assets

-13.12%

Free Cashflow Yield

-76.04%

MGTA Fundamentals

MGTA Revenue

Revenue (TTM)

8.4M

Rev. Growth (Yr)

-80.65%

Rev. Growth (Qtr)

-50.54%

MGTA Earnings

Earnings (TTM)

-50.2M

Earnings Growth (Yr)

-93.26%

Earnings Growth (Qtr)

-29.7%

Breaking Down MGTA Revenue

Last 7 days

-0.2%

Last 30 days

-7.2%

Last 90 days

4.1%

Trailing 12 Months

-57.7%

How does MGTA drawdown profile look like?

MGTA Financial Health

Current Ratio

42.52

MGTA Investor Care

Buy Backs (1Y)

51.61%

Diluted EPS (TTM)

-1.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.3M	10.6M	10.3M	8.4M
2022	2.4M	3.4M	4.3M	5.2M
2021	4.0M	3.5M	3.6M	1.5M
2020	5.9M	0	5.0M	4.2M
2019	3.8M	5.1M	6.1M	6.2M
2018	789.0K	1.3M	1.9M	2.4M
2017	0	0	0	236.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Magenta Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 08, 2023	third rock ventures iv, l.p.	sold	-1,230,000	0.82	-1,500,000	-
Feb 07, 2023	third rock ventures iv, l.p.	sold	-1,826,000	0.83	-2,200,000	-
Nov 30, 2022	gardner jason	acquired	2,820	0.94	3,000	see remarks
Nov 30, 2022	beetham thomas w.	acquired	2,820	0.94	3,000	see remarks
Nov 30, 2022	mahoney stephen f.	acquired	2,820	0.94	3,000	see remarks
Nov 30, 2022	stants kristen	acquired	2,820	0.94	3,000	chief people officer
Nov 30, 2022	deardorf caren	acquired	2,820	0.94	3,000	chief commercial officer
May 31, 2022	gardner jason	acquired	2,970	0.99	3,000	see remarks
May 31, 2022	deardorf caren	acquired	2,970	0.99	3,000	chief commercial officer
May 31, 2022	beetham thomas w.	acquired	2,970	0.99	3,000	see remarks

Which funds bought or sold MGTA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 14, 2023	Axiom Investment Management LLC	sold off	-100	-1,000	-	-%
Jan 20, 2023	HELLMAN JORDAN MANAGEMENT CO INC /MA/	added	142	-83,000	174,000	0.30%
Nov 14, 2022	BREWIN DOLPHIN WEALTH MANAGEMENT LTD	unchanged	-	-2,000	2,000	-%
Sep 09, 2022	B. Riley Wealth Management, Inc.	new	-	13.00	13.00	-%
May 16, 2022	Amalgamated Financial Corp.	new	-	14,000	14,000	-%
May 16, 2022	Parametric Portfolio Associates LLC	new	-	61,000	61,000	-%

Are Funds Buying or Selling MGTA?

Are funds buying MGTA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MGTA

No. of Funds

Unveiling Magenta Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	fairmount funds management llc	9.99%	2,950,487	SC 13D/A
Feb 14, 2024	5am partners vii, llc	4.1%	1,199,228	SC 13G/A
Feb 14, 2024	third rock ventures iv, l.p.	0%	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 09, 2024	gv 2016, l.p.	1.4%	208,697	SC 13G/A
Feb 02, 2024	bcls fund iii investments, lp	9.99%	2,992,028	SC 13G
Feb 02, 2024	ra capital management, l.p.	9.99%	2,995,023	SC 13G
Jan 31, 2024	avidity partners management lp	9.9%	2,922,823	SC 13D
Jan 24, 2024	fairmount funds management llc	9.9%	2,947,317	SC 13D/A
Sep 21, 2023	5am partners vii, llc	7.1%	1,049,030	SC 13G

Recent SEC filings of Magenta Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	424B3	Prospectus Filed
May 09, 2024	8-K	Current Report
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 01, 2024	SC 13D/A	13D - Major Acquisition
Apr 01, 2024	4	Insider Trading
Mar 27, 2024	EFFECT	EFFECT
Mar 25, 2024	CORRESP	CORRESP

Magenta Therapeutics, Inc. News

Latest updates

Magenta Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-50.5%	457	924	4,091	2,960	2,362	1,173	812	884	851	818	682	1,208	897	703	1,233	1,400	1,654	1,630	1,516	1,251	687
Operating Expenses	-75.3%	4,113	16,683	7,375	32,130	-1,677	9,427	18,083	23,834	-39,990	18,245	17,610	18,697	19,065	18,381	21,244	24,637	22,644	19,338	16,350	17,930	16,702
S&GA Expenses	-85.0%	1,309	8,723	5,318	6,132	-3,598	2,209	6,480	7,287	-18,944	7,450	6,481	6,969	6,809	6,595	7,281	5,923	6,120	5,905	5,813	5,540	5,284
R&D Expenses	60.4%	12,764	7,960	139	7,995	1,921	7,218	11,603	16,547	-21,046	10,795	11,129	11,728	12,256	11,786	13,963	18,714	16,524	13,433	10,537	12,390	11,418
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	28.4%	-10,563	-14,763	-11,140	-7,089	-10,116	-7,784	-5,695	-4,881	38,735	-17,427	-16,928	-17,489	-18,168	-17,678	-20,011	-23,237	-20,990	-17,708	-14,834	-16,679	-16,015
Net Income Margin	-23.9%	-5.17*	-4.17*	-3.41*	-4.20*	-5.44*	4.75*	3.20*	-0.21*	-8.88*	-19.42*	-20.13*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-169.2%	-11,854	17,136	-6,544	-35,844	-8,851	16,217	-16,982	-19,768	33,922	-15,198	-13,111	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	113.2%	382	179	192	79.00	83.00	83.00	164	175	194	200	206	220	145	162	175	191	144	162	177	195	148
Current Assets	114.7%	381	177	191	79.00	83.00	82.00	132	142	160	9.00	196	210	135	152	164	180	133	150	165	183	135
Cash Equivalents	149.2%	330	132	157	63.00	49.00	15.00	37.00	57.00	74.00	8.00	159	157	51.00	3.00	143	138	77.00	67.00	87.00	35.00	33.00
Net PPE	5.4%	0.00	0.00	0.00	-	-	0.00	6.00	7.00	7.00	0.00	8.00	8.00	8.00	8.00	9.00	9.00	10.00	10.00	10.00	11.00	11.00
Liabilities	-7.2%	10.00	11.00	14.00	4.00	6.00	9.00	40.00	39.00	43.00	5.00	17.00	17.00	16.00	18.00	16.00	17.00	19.00	20.00	16.00	16.00	14.00
Current Liabilities	-7.0%	9.00	10.00	13.00	4.00	6.00	8.00	13.00	11.00	14.00	5.00	10.00	11.00	9.00	11.00	10.00	10.00	13.00	14.00	10.00	10.00	8.00
Shareholder's Equity	120.7%	373	169	178	75.00	77.00	106	124	136	151	173	190	203	129	144	159	174	125	141	162	180	134
Retained Earnings	-15.4%	-103	-89.40	-78.86	-434	-431	-45.87	-78.90	-365	-348	-17.39	-306	-288	-271	-254	-236	-218	-199	-179	-156	-135	-117
Additional Paid-In Capital	84.3%	476	258	257	509	509	2.00	506	502	500	0.00	496	492	401	398	395	392	325	321	318	315	251
Shares Outstanding	98.1%	29.00	15.00	15.00	61.00	61.00	-	61.00	59.00	59.00	-	54.00	54.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	32.00	-	-	-	56.30*	-	-	-	436	-	-	-	246	-	-	-	364	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-26.0%	-14,941	-11,854	17,136	-6,544	-35,599	-8,851	16,375	-16,853	-19,741	33,937	-14,067	-13,000	-16,774	-13,733	-14,428	-19,205	-16,657	-15,627	-11,507	-15,033	-14,936
Share Based Compensation	180.3%	2,035	726	1,252	416	506	513	-2,745	1,845	1,905	-8,062	3,799	2,134	2,192	2,331	2,366	2,504	2,740	2,062	2,762	2,600	2,577
Cashflow From Investing	33.1%	-5,507	-8,237	-16,880	18,874	26,496	-12,665	-6,881	-129	-40,144	-53,784	16,369	29,889	7,493	-70,974	19,980	14,964	25,395	-5,723	63,808	-43,822	-12,731
Cashflow From Financing	4577.8%	217,847	-4,865	138,439	-	-	-	96,627	49.00	-	-74,565	203	88,856	418	1,179	-159	65,595	1,124	914	95.00	60,725	563

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MGTA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 13,078	$ 5,847
General and administrative	5,640	2,312
Total operating expenses	18,718	8,159
Loss from operations	(17,844)	(7,683)
Other income/(expense):
Interest income	4,222	606
Loss on currency exchange, net	(12)	(9)
Other expense	(114)	(3)
Total other income	4,096	594
Net loss	$ (13,748)	$ (7,089)
Net loss per share attributable to common stockholders, basic	$ (0.54)	$ (8.1)
Net loss per share attributable to common stockholders, diluted	$ (0.54)	$ (8.1)
Weighted-average number of shares of common stock outstanding, used in computing net loss per share of common stock, basic	25,665,475	874,709
Weighted-average number of shares of common stock outstanding, used in computing net loss per share of common stock, diluted	25,665,475	874,709
Comprehensive loss:
Net Income (Loss)	$ (13,748)	$ (7,089)
Other comprehensive (loss)/income:
Change in unrealized (losses)/gains related to available-for-sale debt securities	(74)	104
Total other comprehensive (loss)/income	(74)	104
Total comprehensive loss	(13,822)	(6,985)
Related Party [Member]
Revenues:
License revenue - related party	$ 874	$ 476

MGTA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 329,724	$ 132,325
Short-term investments	47,312	41,393
Receivable from related party	435	294
Unbilled receivable from related party	441	184
Prepaid expenses and other current assets	3,014	3,255
Total current assets	380,926	177,451
Property and equipment, net	195	185
Right-of-use operating lease assets	530	615
Other assets and restricted cash	811	1,154
Total assets	382,462	179,405
Current liabilities:
Accounts payable	2,612	2,610
Accrued expenses	5,847	6,504
Current portion of deferred revenue - related party	100	100
Current portion of operating lease liabilities	400	417
Total current liabilities	8,959	9,631
Deferred revenue - related party	719	736
Long-term operating lease liabilities	97	168
Total liabilities	9,775	10,535
Commitments and contingencies (Note 15)
Stockholders' equity/(deficit):
Preferred stock; $0.001 par value per share; authorized shares - 10,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding - none at March 31, 2024 and December 31, 2023	0	0
Common stock; $0.001 par value per share; authorized shares -150,000,000 at March 31, 2024 and December 31, 2023; issued and outstanding shares - 29,348,626 and 14,817,696 at March 31, 2024 and December 31, 2023, respectively	29	15
Additional paid-in capital	475,856	258,231
Accumulated deficit	(103,171)	(89,423)
Accumulated other comprehensive (loss)/income	(27)	47
Total stockholders' equity	372,687	168,870
Total liabilities and stockholders' equity	$ 382,462	$ 179,405

About Magenta Therapeutics, Inc.

Magenta Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Magenta Therapeutics, Inc.? What does MGTA stand for in stocks?

MGTA is the stock ticker symbol of Magenta Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Magenta Therapeutics, Inc. (MGTA)?

As of Tue Apr 30 2024, market cap of Magenta Therapeutics, Inc. is 21.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MGTA stock?

You can check MGTA's fair value in chart for subscribers.

What is the fair value of MGTA stock?

You can check MGTA's fair value in chart for subscribers. The fair value of Magenta Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Magenta Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MGTA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Magenta Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether MGTA is over valued or under valued. Whether Magenta Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Magenta Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MGTA.

What is Magenta Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, MGTA's PE ratio (Price to Earnings) is -0.44 and Price to Sales (PS) ratio is 2.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MGTA PE ratio will change depending on the future growth rate expectations of investors.